Serum levels of MIP-1β and rantes in HIV-1 subtype CRF01_ae infected patients with different rates of disease progression

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 39, Issue 5, 2008, Pages 863-866

  Chuenchitra, Thippawan ^a   Wasi, Chantapong ^b   De Souza, Mark ^c   Nitayaphan, Sorachai ^b   Louisirirotchanakul, Suda ^b   Sutthent, Ruengpung ^b   Brown, Arthur E ^d   Birx, Deborah L ^e   Polonis, Victoria R ^c  

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c US Military HIV Research Program   (United States)

^d US Army Medical Materiel Development Activity   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCL4 PROTEIN, HUMAN; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES; UNCLASSIFIED DRUG; VIRUS RNA;

ARTICLE; BLOOD; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOPHYSIOLOGY; VIRUS LOAD;

CD4 LYMPHOCYTE COUNT; CHEMOKINE CCL4; CHEMOKINE CCL5; DISEASE PROGRESSION; HIV INFECTIONS; HIV-1; HUMANS; RNA, VIRAL; VIRAL LOAD;

EID: 60249085955     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophagetropic HIV-1. Science 1996; 272: 1955-8.
2. Aukrust P, Muller F, Froland SS. Circulating levels of RANTES in human immunodeficiency virus type 1 infection: effect of potent antiretroviral therapy. J Infect Dis 1998; 177: 1091-6.
3. Chuenchitra T, Wasi C, Louisirirojchanakul S, et al. Longitudinal study of humoral immune responses in HIV type 1 subtype CRF01_AE (E)-infected Thai patients with different rates of disease progression. AIDS Res Hum Retroviruses 2003; 19: 293-305.
4. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CDS+ T cells [see comments]. Science 1995; 270: 1811-5.
5. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273: 1856-62.
6. de Roda Husman AM, Koot M, Cornelissen M, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection [see comments]. Ann Intern Med 1997; 127: 882-90.
7. Ferbas J, Giorgi JV, Amini S, et al. Antigen-specific production of RANTES, macrophage inflammatory protein (MIP)-1alpha, and MIP-1beta in vitro is a correlate of reduced human immunodeficiency virus burden in vivo. J Infect Dis 2000; 182: 1247-50.
8. Garcino-Demo A, Moss RB, Margolick JB, et al. Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free atatus. Proc Natl Acad Sci USA 1999; 96: 11986-91.
9. Greco G, Barker E, Leve JA. Differences in HIV replication in CD4+ lymphocytes are not related to beta-chemokine production. AIDS Res Hum Retrovirus 1998; 14: 1407-11.
10. Hittinger G, Poggi C, Delbeke E, Profizi N, Lafeuillade A. Correlation between plasma levels of cytokines and HIV-1 RNA copy number in HIV-infected patients. Infection 1998; 26: 100-3.
11. Jennes W, Sawadogo S, Koblavi-Deme S, et al. Positive association between beta-chemokine-producing T cells and HIV type 1 viral load in HIV-infected subjects in Abidjan, Cote d'Ivoire. AIDS Res Hum Retroviruses 2002; 18: 171-7.
12. Kinter AL, Ostrowski M, Goletti D, et al. HIV replication in CD4+ T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects of endogenous beta-chemokines and the viral inductive effects of other endogenous cytokines. Proc Natl Acad Sci USA 1996; 93: 14076-81.
13. Kreuzer KA, Rockstroh JK, Kupfer B, Spengler U. Endogenous levels of C-C chemokines MIP-1alpha, MIP-1beta, and RANTES do not reflect the disease course in HIV-seropositive individuals, Int J Clin Lab Res 2000; 30: 163-8.
14. Krowka JF, Gesner ML, Ascher MS, Sheppard HW. Lack of associations of chemotactic cytokines with viral burden, disease progression, or lymphocyte subsets in HIV-infected individuals. Clin Immunol Immunopathol 1997; 85: 21-7.
15. Levy JA. HIV and pathogenesis of AIDS. Washington, DC: ASM Press, 1998.
16. McKenzie SW, Dallalio G, North M, Frame P, Means RT, Jr. Serum chemokine levels in patients with non-progressing HIV infection. AIDS 1996; 10: F29-33.Picker LJ. Immunopathogenesis of acute AIDS virus infection. Curr Opin Immunol 2006; 18: 399-405.
17. Michael NL, Chang G, Louie LG, et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997; 3: 338-40.
18. Paxton WA, Neumann AU, Kang S, et al. RANTES production from CD4+ lymphocytes correlates with host genotype and rates of human immunodeficiency virus type 1 disease progression. J Infect Dis 2001; 183: 1678-81.
19. Picker LJ. Immunopathogenesis of acute AIDS virus infection. Curr Opin Immunol 2006; 18: 309-405.
20. Ping YE, Kazanjian P, Kunkel SL, Kirschner DE. Lack of good correlation of serum CC-chemokine levels with human immunodeficiency virus-1 disease stage and response to treatment. J Lab Clin Med 2004; 143: 310-9.
21. Polo S, Veglia F, Malnati MS, et al. Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection. AIDS 1999; 13: 447-54.
22. Trumpfheller C, Tenner-Racz K, Racz P, Fleischer B, Frosch S. Expression of macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES genes in lymph nodes from HIV+ individuals: correlation with a Th 1-type cytokine response. Clin Exp Immunol 1998; 112: 92-9.
23. Ullum H, Cozzi Lepri A, Victor J, et al. Production of beta-chemokines in human immunodeficiency virus (HIV) infection: evidence that high levels of macrophage inflammatory protein-1 beta are associated with a decreased risk of HIV disease progression. J Infect Dis 1998; 177: 331-6.
24. Vitale F, Bonura F, Perna AM, Ajello F, Romano N. Serum RANTES levels in HIV-positive individuals and in HIV-negative exposed health-care workers. Infection 1997; 25: 381-2.
25. Walker CM, Steimer KS, Rosenthal KL, Levy JA. Identification of human immunodeficiency virus (HIV) envelope type-specific T helper cells in an HIV-infected individual. J Clin Invest 1988; 82: 2172-5.
26. Weiss L, Si-Mohamed A, Giral P, et al. Plasma levels of monocyte chemoattractant protein-1 but not those of macrophage inhibitory protein-1 alpha and RANTES correlate with virus load in human immunodeficiency virus infection. J Infect Dis 1997; 176: 1621-4.
27. Zanussi S, D'Andrea M, Simonelli C, Tirelli U, De Paoli P, Serum levels of RANTES and MIP-1 alpha in HIV-positive long-term survivors and progresser patients. AIDS 1996; 10: 1431-2.